000			02297ngm a2200505 a 4500
001			HST4541
003			UkLoHST
006			m c
007			cr|cna|||a||||
007			vz|czazum
008			170710s2017 enk|||||||||||s|||v|eng d
028	5	0	_a4541 _bHenry Stewart Talks
035			_a(UkLoHST)3542
040			_aUkLoHST _beng _cUkLoHST
100	1		_aLuzzatto, Lucio, _u(Muhimbili University of Health and Applied Sciences, Tanzania) _4spk
245	1	0	_aComplement in PNH and other hemolytic anaemias _h[electronic resource] : _bpart 3 of 3 / _cLucio Luzzatto.
246	3		_aComplement in Paroxysmal nocturnal hemoglobinuria and other hemolytic anemias. Part 3
246	3		_aComplement in PNH and other hemolytic anaemias. Part 3
260			_aLondon : _bHenry Stewart Talks, _c2017.
300			_a1 online resource (1 streaming video file (27 min.) : _bcolor, sound).
490	1		_aThe complement system, _x2056-452X
500			_aAnimated audio-visual presentation with synchronized narration.
500			_aTitle from title frames.
505	0		_aContents: Complement-targeted therapy for PNH -- Mechanism of (iatrogenic) hemolysis in PNH -- Pathogenesis of PNH -- Anaemias due to intravascular hemolysis -- Bone marrow failure and PNH -- Somatic mutations in PNH -- Clinical burden of PNH -- PNH: issues in management -- Eculizumab (anti-C5 Ab): targeted therapy for PNH.
506			_aAccess restricted to subscribers.
538			_aMode of access: World Wide Web.
650		0	_aComplement (Immunology)
650		0	_aHemolytic anemia.
650		0	_aImmunologic diseases.
650		0	_aParoxysmal hemoglobinuria.
650		2	_aAnemia, Hemolytic.
650		2	_aAntibodies, Monoclonal, Humanized.
650		2	_aBone Marrow.
650		2	_aComplement Activation _xdrug effects.
650		2	_aComplement System Proteins.
650		2	_aeculizumab.
650		2	_aErythrocytes.
650		2	_aHemoglobinuria, Paroxysmal _xdrug therapy.
650		2	_aHemoglobinuria, Paroxysmal _xpathology.
650		2	_aHemolysis _xdrug effects.
650		2	_aIatrogenic Disease.
830		0	_aHenry Stewart talks. _pBiomedical & life sciences collection. _pComplement system.
856	4	0	_uhttps://hstalks.com/bs/3542/
856	4	2	_uhttps://hstalks.com/bs/p/1036/ _3Series
999			_c76501 _d76501